Radiotherapy
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MoreAnalysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Scientific Reports 2022 October 4 [Link] Kui Fan, Chuan-Long Zhang, Bo-Hui Zhang, Meng-Qi Gao, Yun-Chuan Sun Abstract Mesothelioma lies one of the most malignant tumors, in which the identification of the corresponding biomarkers is extremely critical. This study aims to investigate the prognostic value of enhancer homolog 2 (EZH2) mRNA expression in mesothelioma patients accompanied…
Read MoreBMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation
BMC Cancer 2022 September 15 [Link] Nguyen Truong Duc Hoang, Ghmkin Hassan, Tomoya Suehiro, Yuichi Mine, Tohru Matsuki, Makiko Fujii Abstract Background: Malignant mesothelioma (MM) is an aggressive mesothelial cell cancer type linked mainly to asbestos inhalation. MM characterizes by rapid progression and resistance to standard therapeutic modalities such as surgery, chemotherapy, and radiotherapy. Our…
Read MoreProposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
Journal of Thoracic Disease 2022 August [Link] Olivia Lauk, Thomas Neuer, Bianca Battilana, Ilhan Inci, Katarzyna Furrer, Walter Weder, Masaki Hashimoto, Isabelle Opitz Abstract Background: Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish…
Read MoreTraining and validation of a knowledge-based dose-volume histogram predictive model in the optimisation of intensity-modulated proton and volumetric modulated arc photon plans for pleural mesothelioma patients
Radiation Oncology 2022 August 26 [Link] Davide Franceschini, Luca Cozzi, Antonella Fogliata, Beatrice Marini, Luciana Di Cristina, Luca Dominici, Ruggero Spoto, Ciro Franzese, Pierina Navarria, Tiziana Comito, Giacomo Reggiori, Stefano Tomatis, Marta Scorsetti Abstract Background: To investigate the performance of a narrow-scope knowledge-based RapidPlan (RP) model for optimisation of intensity-modulated proton therapy (IMPT) and volumetric…
Read MoreSingle-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2022 August 3 [Link] Giuseppe Mangiameli, Edoardo Bottoni, Umberto Cariboni, Giorgio Maria Ferraroli, Emanuela Morenghi, Veronica Maria Giudici, Emanuele Voulaz, Marco Alloisio, Alberto Testori Abstract Objectives: We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period,…
Read MoreSecond Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review
Journal of Clinical Medicine 2022 June 10 [Link] Alice Bellini, Sara Mazzarra, Sara Sterrantino, Desideria Argnani, Franco Stella Abstract Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumour with poor prognosis. To date, a multimodality treatment, including chemotherapy and surgery, with or without radiotherapy, is the gold standard therapy for selected patients with epithelioid and…
Read MoreMultimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients
Cancers 2022 April 30 [Link] Arnulf Holzknecht, Oliver Illini, Maximilian J Hochmair, Dagmar Krenbek, Ulrike Setinek, Florian Huemer, Erwin Bitterlich, Christoph Kaindl, Vladyslav Getman, Ahmet Akan, Michael Weber, Gunther Leobacher, Arschang Valipour, Michael R Mueller, Stefan B Watzka Abstract Malignant pleural mesothelioma (MPM) is a rare pleural cancer associated with asbestos exposure. According to current…
Read MoreRadiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab
Cureus 2022 February 12 [Link] Rebekah Rittberg, Elisa Chan, Stephen Yip, Deepu Alex, Cheryl Ho Abstract Abscopal effect is a rare phenomenon in which treatment benefit from radiotherapy (RT) is seen outside the target field due to activation of the immune system inducing an anti-tumor effect. This phenomenon has been reported in cancer patients receiving…
Read MoreAn Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Lung Cancer 2022 March 2 [Link] Alexander Davis, Helen Ke, Steven Kao, Nick Pavlakis Abstract The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence…
Read More